Literature DB >> 28499244

MicroRNA-24-1 suppresses mouse hepatoma cell invasion and metastasis via directly targeting O-GlcNAc transferase.

Yubo Liu1, Huang Huang1, Meijun Liu1, Qiong Wu1, Wenli Li1, Jianing Zhang2.   

Abstract

MicroRNAs (miRNAs) are endogenous non-coding regulatory RNAs involved in multiple cellular processes. Emerging evidences showed that miRNAs are involved in changing the cell surface glycosylation modification and oncogenesis. In this study, the role of miRNA-24-1 in O-GlcNAcylation and metastasis of mouse hepatocarcinoma cells was investigated. miRNAs expression array profiles were obtained from mouse hepatocarcinoma cell lines Hca-P and Hca-F with the low/high lymphatic metastasis potential, respectively. Based on the miRNAs expression array profiles, miRNA-24-1 expression was found to exhibit converse coincidence with metastasis potential, O-GlcNAc transferase (OGT) expression and O-GlcNAcylation. Dual-luciferase reporter assay revealed that miRNA-24-1 specifically binds to 3'-UTR of OGT. Furthermore, transfecting mouse hepatocarcinoma cells with miR-24-1 mimic and antisense oligonucleotide showed miR-24-mediates OGT expression silencing. This silencing is associated with the suppression of cell metastasis potential, down-regulation of the O-GlcNAcylation on c-Myc and decrease of c-Myc expression at the protein level rather than the mRNA level. Collectively, these results suggested that as a tumor suppressor, miR-24-1 may regulate mouse hepatocarcinoma cells migration and invasion, at least partially through targeting OGT, which could regulate the O-GlcNAcylation and the stability of this oncoprotein c-Myc. This may give insight into a novel mechanism and therapy of tumor lymphatic metastasis.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Metastasis; OGT; c-Myc; miRNA

Mesh:

Substances:

Year:  2017        PMID: 28499244     DOI: 10.1016/j.biopha.2017.05.007

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  8 in total

Review 1.  O-GlcNAc in cancer: An Oncometabolism-fueled vicious cycle.

Authors:  John A Hanover; Weiping Chen; Michelle R Bond
Journal:  J Bioenerg Biomembr       Date:  2018-03-29       Impact factor: 2.945

2.  Blocked O-GlcNAc cycling disrupts mouse hematopoeitic stem cell maintenance and early T cell development.

Authors:  Lara K Abramowitz; Christelle Harly; Arundhoti Das; Avinash Bhandoola; John A Hanover
Journal:  Sci Rep       Date:  2019-08-29       Impact factor: 4.379

3.  A novel hypoxic long noncoding RNA KB-1980E6.3 maintains breast cancer stem cell stemness via interacting with IGF2BP1 to facilitate c-Myc mRNA stability.

Authors:  Pengpeng Zhu; Fang He; Yixuan Hou; Gang Tu; Qiao Li; Ting Jin; Huan Zeng; Yilu Qin; Xueying Wan; Yina Qiao; Yuxiang Qiu; Yong Teng; Manran Liu
Journal:  Oncogene       Date:  2021-01-19       Impact factor: 9.867

Review 4.  Hepigenetics: A Review of Epigenetic Modulators and Potential Therapies in Hepatocellular Carcinoma.

Authors:  Mohamed H Yousef; Hassan A N El-Fawal; Anwar Abdelnaser
Journal:  Biomed Res Int       Date:  2020-11-24       Impact factor: 3.411

Review 5.  Intricate crosstalk between MYC and non-coding RNAs regulates hallmarks of cancer.

Authors:  Lotteke J Y M Swier; Agnieszka Dzikiewicz-Krawczyk; Melanie Winkle; Anke van den Berg; Joost Kluiver
Journal:  Mol Oncol       Date:  2018-12-05       Impact factor: 6.603

Review 6.  Functional Analysis of O-GlcNAcylation in Cancer Metastasis.

Authors:  Donglu Wu; Jingji Jin; Zhidong Qiu; Da Liu; Haoming Luo
Journal:  Front Oncol       Date:  2020-10-27       Impact factor: 6.244

Review 7.  Epigenetic Regulation of Glycosylation in Cancer and Other Diseases.

Authors:  Rossella Indellicato; Marco Trinchera
Journal:  Int J Mol Sci       Date:  2021-03-15       Impact factor: 5.923

Review 8.  Role of O-Linked N-Acetylglucosamine Protein Modification in Cellular (Patho)Physiology.

Authors:  John C Chatham; Jianhua Zhang; Adam R Wende
Journal:  Physiol Rev       Date:  2020-07-30       Impact factor: 37.312

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.